FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Medical Devices

Shuren Discusses Device Reporting Changes

In an online post, CDRH director Jeff Shuren discusses the end to the Centers Alternative Summary Reporting program and other changes to medical devic...

Guide on Submitting Promo Labeling/Ad Materials

FDA posts a final guidance entitled Providing Regulatory Submissions in Electronic and Non-Electronic Format Promotional Labeling and Advertising Mat...

Medical Devices

Teleflex Recalls Sheridan Endotracheal Tubes

Teleflex Medical recalls multiple models of the Hudson RCI Sheridan and Sheridan Endotracheal Tubes due to complaints about the devices connector disc...

Federal Register

Draft Guide on Opioid Benefit-Risk Assessments

Federal Register notice: FDA makes available a draft guidance entitled Opioid Analgesic Drugs: Considerations for Benefit-Risk Assessment Framework.

Human Drugs

Infusion Options Recalls Sterile Products

Infusion Options recalls all lots of its sterile products due to a lack of sterility assurance.

Federal Register

Hearing on Standards for Future Opioid Analgesic Approvals

Federal Register notice: FDA announces a 9/17 public hearing entitled Standards for Future Opioid Analgesic Approvals and Incentives for New Therapeut...

Federal Register

Info Collection for GRAS Substance Notifications

Federal Register notice: FDA submits to OMB an information collection extension for Substances Generally Recognized as Safe (GRAS): Notification Proce...

Federal Register

Pediatric Oncology Subcommittee Meeting Amended

Federal Register notice: FDA amends a 5/6 Federal Register notice about a 6/20 meeting of the Oncologic Drugs Advisory Committees Pediatric Oncology S...

Human Drugs

Opioid Benefit/Risk Framework Guidance

FDA issues new guidance and schedules a public meeting on its benefit/risk assessment framework for opioid analgesics.

Human Drugs

Melinta Therapeutics Priority Review for Baxdela sNDA

FDA accepts for priority review a Melinta Therapeutics supplemental NDA for Baxdela (delafloxacin) to expand the current indication to include adult p...